A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients

Journal of Neuro-Oncology

Volumn 88, Issue 3, 2008, Pages 353-357

  Pan, Edward ^a   Mitchell, Susan B ^b   Tsai, Jerry S ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b FLORIDA HOSPITAL   (United States)

^c Clintuition   (United States)

Author keywords

BCNU wafers; GBM; Gliadel; Glioblastoma; Radiotherapy; Safety; Temozolomide; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; DEXAMETHASONE; GLIADEL WAFER; MANNITOL; OLANZAPINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGITATION; APPETITE DISORDER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFUSION; DELIRIUM; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENCEPHALITIS; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; LETHARGY; MEDICAL RECORD; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PSYCHOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY HESITANCY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG IMPLANTS; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; RADIOTHERAPY; RETROSPECTIVE STUDIES;

EID: 44649084230     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9576-7     Document Type: Article

References (20)

1. Surawicz TS, McCarthy BJ, Kupelian V et al (1999) Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-oncology 1:14-25
2. Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10-14
3. Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710
4. Shrieve DC, Alexander E 3rd, Black PM et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome. J Neurosurg 90:72-77
5. Temodar® [prescribing information] (2005) Schering Corp, Kenilworth, NJ
6. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
7. Gliadel® Wafer [prescribing information] (2007) MGI PHARMA INC., Bloomington, MN
8. Fung LK, Shin M, Tyler B, Brem H, Saltzman WM (1996) Chemotherapeutic drugs released from polymers: Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 13:671-682
9. Dang W, Daviau T, Ying P et al (1996) Effects of GLIADEL® wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release 42:83-92
10. Domb AJ, Rock M, Schwartz J et al (1994) Metabolic disposition and elimination studies of a radiolabelled biodegradable polymeric implant in the rat brain. Biomaterials 15:681-688
11. Kleinberg LR, Weingart J, Burger P et al (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: Implications for patient management. Cancer Invest 22:1-9
12. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5:79-88
13. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E (2006) Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir 148:269-275
14. Spiegel BM, Esrailian E, Laine L, Chamberlain MC (2007) Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: A meta-analysis. CNS Drugs 21:775-787
15. LaRocca RV, Hodes J, Villanueva WG et al (2006) A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion (abstract TA-28). Neuro-oncology 8:445
16. National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/forms/CTCAEv3.pdf. Cited December 4, 2007
17. Weber EL, Goebel EA (2005) Cerebral edema associated with Gliadel wafers: Two case studies. Neuro-oncology 7:84-89
18. Gururangan S, Cokgor L, Rich JN et al (2001) Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncology 3:246-250
19. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R (2005) A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neuro-oncology 72:241-244
20. Laws ER, Parney IF, Huang W et al (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J Neurosurg 99:467-473